$2.59 Billion is the total value of Deep Track Capital, LP's 63 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IONS | IONIS PHARMACEUTICALS INC | $128,553,370 | +10.6% | 2,834,069 | 0.0% | 4.96% | -7.8% | |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $81,993,577 | -11.8% | 3,546,435 | 0.0% | 3.16% | -26.5% | |
| TVTX | TRAVERE THERAPEUTICS INC | $65,887,800 | -41.8% | 7,370,000 | 0.0% | 2.54% | -51.5% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $51,954,865 | -22.9% | 3,187,415 | 0.0% | 2.00% | -35.7% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $35,365,302 | -29.6% | 2,778,107 | 0.0% | 1.36% | -41.3% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $34,950,000 | -2.1% | 15,000,000 | 0.0% | 1.35% | -18.4% | |
| NRIX | NURIX THERAPEUTICS INC | $23,562,944 | -21.3% | 2,997,830 | 0.0% | 0.91% | -34.4% | |
| SLN | SILENCE THERAPEUTICS PLCads | $19,164,516 | +78.5% | 1,951,580 | 0.0% | 0.74% | +48.9% | |
| PNT | POINT BIOPHARMA GLOBAL INC | $18,553,039 | -26.4% | 2,781,565 | 0.0% | 0.72% | -38.6% | |
| ZURA BIO LTD | $16,651,800 | -19.5% | 2,523,000 | 0.0% | 0.64% | -32.9% | ||
| EWTX | EDGEWISE THERAPEUTICS INC | $15,757,500 | -26.1% | 2,750,000 | 0.0% | 0.61% | -38.4% | |
| PRTA | PROTHENA CORP PLCput | $12,062,500 | -29.3% | 250,000 | 0.0% | 0.47% | -41.0% | |
| NUVB | NUVATION BIO INC | $10,345,722 | -25.6% | 7,720,688 | 0.0% | 0.40% | -37.9% | |
| RLMD | RELMADA THERAPEUTICS INC | $8,513,454 | +22.0% | 2,837,818 | 0.0% | 0.33% | +1.9% | |
| GHRS | GH RESEARCH PLCordinary shares | $5,018,970 | -15.3% | 499,400 | 0.0% | 0.19% | -29.2% | |
| HRTX | HERON THERAPEUTICS INC | $2,149,305 | -11.2% | 2,086,704 | 0.0% | 0.08% | -25.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.